Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obstructive sleep apnea
Biotech
Apnimed's sleep apnea star goes 2 for 2 in phase 3
Patients receiving AD109 had a 46.8% reduction in a measure of sleep apnea severity, highlighting the asset's potential to treat the common condition.
Darren Incorvaia
Jul 23, 2025 6:00am
Apnimed eyes FDA sleep apnea submission after positive results
May 19, 2025 6:00am
Resmed debuts wearable, at-home sleep apnea test
Apr 4, 2025 12:00pm
Inspire Medical discloses DOJ civil false claims investigation
Feb 11, 2025 3:00pm
Takeda stops phase 2 post-anesthesia trial over slow enrollment
Oct 31, 2024 5:29am
FDA clears Withings' contactless mat for diagnosing sleep apnea
Sep 10, 2024 10:00am
